An interventional study of Remote Patient Monitoring and Self-monitoring of hypertension-related factors in Hypertension, Health Behavior and Healthcare Patient Acceptance, sponsored by Tulane University. Completed at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Tulane University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hypertension by Tulane University — 2 open to participants now, 7 under way, none of them phase 3. Hypertension · Tulane University.
Among the 17 studies in Hypertension by Tulane University, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 16th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 17 studies in Hypertension by Tulane University are open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
Tulane University · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1973; this study’s year is marked. 1 started in 2024.
This study's enrollment of 50 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 1,176 across the 15 interventional studies, 5,874 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
3 of the studies in Hypertension by Tulane University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183763Tulane UniversityMedication Adherence Program | 2027-04-30 |
| NCT06133322Tulane UniversityBlood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED) | 2027-06-30 |
| NCT06065098Tulane UniversityChurch-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hypertension by Tulane University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot clinical trial is to determine feasibility and explore whether immediate versus delayed patient financial incentives improve patient engagement with self-monitoring of blood pressure in patients with uncontrolled hypertension at Louisiana federally qualified health centers (FQHCs). The main questions it aims to answer are:
Participants will:
Researchers will compare the immediate and delayed incentive groups to see if there are differences in blood pressure monitoring adherence rates and blood pressure control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* instructions for participating in a 2-month remote patient monitoring program * home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking * wrist-worn sensor and associated smartphone app * weekly adherence feedback to home blood pressure monitoring * immediate financial incentives for home blood pressure monitoring distributed weekly
Behavioral: Remote Patient Monitoring · Behavioral: Self-monitoring of hypertension-related factors · Behavioral: Immediate financial incentives
* instructions for participating in a 2-month remote patient monitoring program * home blood pressure monitor and associated smartphone app, which includes a module for logging medication-taking * wrist-worn sensor and associated smartphone app * weekly adherence feedback to home blood pressure monitoring * delayed financial incentives for home blood pressure monitoring distributed at the end of the study
Behavioral: Remote Patient Monitoring · Behavioral: Self-monitoring of hypertension-related factors · Behavioral: Delayed financial incentives
Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study. Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol. Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity. Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)
Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)
Between-group Difference in Weekly Adherence to Blood Pressure Monitoring
Weekly adherence to blood pressure monitoring will be defined as the number of days that the participant used the home blood pressure monitor at least once, captured in the blood pressure monitoring app usage data. For each week of their monitoring period, the number of days that a participant had at least one blood pressure measurement will be calculated (0-7 days). Participants' weekly adherence scores will then be averaged over the 8-week monitoring period into a single aggregate score capturing their average weekly adherence to blood pressure monitoring.
Time frame: 8 weeks
Between-group Mean Difference in Change in Systolic Blood Pressure
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in systolic blood pressure (SBP) will be calculated as participants' SBP value at the 8-week follow-up visit minus their SBP value at the baseline visit.
Time frame: baseline, 8 weeks
Between-group Mean Difference in Change in Diastolic Blood Pressure
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in diastolic blood pressure (DBP) will be calculated as participants' DBP value at the 8-week follow-up visit minus their DBP value at the baseline visit.
Time frame: baseline, 8 weeks
Between-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg)
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Blood pressure control will be defined as systolic \<130 mm Hg and diastolic \<80 mm Hg.
Time frame: 8 weeks
Between-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg)
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Systolic blood pressure control will be defined as systolic \<130 mm Hg.
Time frame: 8 weeks
Number of Patients Reached for Recruitment
Number of patients with whom the study team connected by phone or who participated in a recruitment conversation in clinic
Time frame: 3 months
Number of Patients Assessed for Eligibility
Number of patients who begin eligibility screener
Time frame: 3 months
Number of Patients Enrolled
Number of patients who consent and are randomized
Time frame: 3 months
Percentage of Intended Intervention Received
The total amount of financial incentives delivered to each participant during the blood pressure monitoring period will be calculated, then divided by the total possible financial incentive amount to represent each participant's percentage of possible financial incentives received. Mean scores in each study arm will be reported as a measure of the percentage of the intended financial incentive intervention that was received by participants in each group.
Time frame: 2 months
| Milestone | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Started | 25 | 25 |
| Completed | 24 | 24 |
| Not completed | 1 | 1 |
Weekly adherence to blood pressure monitoring will be defined as the number of days that the participant used the home blood pressure monitor at least once, captured in the blood pressure monitoring app usage data. For each week of their monitoring period, the number of days that a participant had at least one blood pressure measurement will be calculated (0-7 days). Participants' weekly adherence scores will then be averaged over the 8-week monitoring period into a single aggregate score capturing their average weekly adherence to blood pressure monitoring.
| Days per week | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Between-group Difference in Weekly Adherence to Blood Pressure Monitoring | 5.11 ± 2.11 | 5.73 ± 1.90 |
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in systolic blood pressure (SBP) will be calculated as participants' SBP value at the 8-week follow-up visit minus their SBP value at the baseline visit.
| mmHg | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Between-group Mean Difference in Change in Systolic Blood Pressure | -2.40 ± 17.89 | -9.49 ± 26.29 |
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Change in diastolic blood pressure (DBP) will be calculated as participants' DBP value at the 8-week follow-up visit minus their DBP value at the baseline visit.
| mmHg | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Between-group Mean Difference in Change in Diastolic Blood Pressure | -0.94 ± 11.95 | -5.11 ± 14.30 |
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Blood pressure control will be defined as systolic \<130 mm Hg and diastolic \<80 mm Hg.
| Participants | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Between-group Difference in the Percentage of Participants With Blood Pressure Control (<130/80 mm Hg) | 10 | 6 |
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines. Systolic blood pressure control will be defined as systolic \<130 mm Hg.
| Participants | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Between-group Difference in the Percentage of Participants With Systolic Blood Pressure Control (<130 mm Hg) | 13 | 9 |
Number of patients with whom the study team connected by phone or who participated in a recruitment conversation in clinic
| Participants | Recruitment Sample |
|---|---|
| Number of Patients Reached for Recruitment | 107 |
Number of patients who begin eligibility screener
| Participants | Reachable Sample |
|---|---|
| Number of Patients Assessed for Eligibility | 77 |
Number of patients who consent and are randomized
| Participants | Eligible Sample |
|---|---|
| Number of Patients Enrolled | 50 |
The total amount of financial incentives delivered to each participant during the blood pressure monitoring period will be calculated, then divided by the total possible financial incentive amount to represent each participant's percentage of possible financial incentives received. Mean scores in each study arm will be reported as a measure of the percentage of the intended financial incentive intervention that was received by participants in each group.
| percentage of total possible incentives | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Percentage of Intended Intervention Received | 79.60 ± 30.37 | 87.30 ± 26.17 |
Collected over Two months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Financial Incentives for BP Monitoring | 0/24 (0%) | 2/24 (8.3%) | 1/24 (4.2%) |
| Delayed Financial Incentives for BP Monitoring | 0/24 (0%) | 0/24 (0%) | 1/24 (4.2%) |
| Event | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| Hospitalization due to food poisoningInfections and infestations | 1/24 | 0/24 |
| Hospitalization due to motor vehicle accidentInjury, poisoning and procedural complications | 1/24 | 0/24 |
| Event | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring |
|---|---|---|
| ED visit due to dizzinessNervous system disorders | 1/24 | 1/24 |
| Age, Continuous(years) | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring | Total |
|---|---|---|---|
| Mean | 56.32 ± 10.04 | 59.08 ± 9.14 | 57.70 ± 9.60 |
| Sex: Female, Male(Participants) | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 9 | 9 | 18 |
| Race (NIH/OMB)(Participants) | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 20 | 43 |
| White | 1 | 5 | 6 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 20 | 22 | 42 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(Participants) | Immediate Financial Incentives for BP Monitoring | Delayed Financial Incentives for BP Monitoring | Total |
|---|---|---|---|
| United States | 25 | 25 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2024 to primary completion in Sep 2025, 15 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 15 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tulane University